Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITPR3 | Q14573 | 3/20 | 0.36 |
| ▸ | BTN3A1 | O00481 | 2/20 | 0.33 |
| ▸ | ITPR2 | Q14571 | 1/20 | 0.32 |
| ▸ | ITPR1 | Q14643 | 1/20 | 0.32 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.31 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28926554 | 1.00 | ITPR3 (0.36) | ITPR3BTN3A1ITPR2ITPR1P2RY2 | |
| SCHEMBL28639733 | 1.00 | ITPR3 (0.36) | ITPR3BTN3A1ITPR2ITPR1P2RY2 | |
| SCHEMBL1983636 | 1.00 | ITPR3 (0.36) | ITPR3BTN3A1ITPR2ITPR1P2RY2 | |
| SCHEMBL28506261 | 1.00 | ITPR3 (0.36) | ITPR3BTN3A1ITPR2ITPR1P2RY2 | |
| SCHEMBL28644610 | 1.00 | ITPR3 (0.36) | ITPR3BTN3A1ITPR2ITPR1P2RY2 | |
| SCHEMBL23211993 | 1.00 | ITPR3 (0.36) | ITPR3BTN3A1ITPR2ITPR1P2RY2 | |
| Water SCHEMBL28654980 | 0.98 | ITPR3 (0.35) | ITPR3BTN3A1ITPR2ITPR1P2RY2 | |
| SCHEMBL134178 | 0.98 | ITPR3 (0.37) | ITPR3BTN3A1ITPR2ITPR1P2RY2 | |
| SCHEMBL544344 | 0.98 | ITPR3 (0.37) | ITPR3BTN3A1ITPR2ITPR1P2RY2 | |
| SCHEMBL12475062 | 0.98 | ITPR3 (0.37) | ITPR3BTN3A1ITPR2ITPR1P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116573615-B | Hydrogen peroxide and purification method thereof | 乳源东阳光电化厂 | 2024-12-03 | — | — | CN | claimed |
| CN-114699417-B | Application of sodium inositol hexaphosphate in intestinal rehabilitation of children short bowel syndrome | 上海交通大学医学院附属新华医院 | 2024-01-09 | — | — | CN | claimed |
| CN-116573615-A | Hydrogen peroxide and purification method thereof | 乳源东阳光电化厂 | 2023-08-11 | — | — | CN | claimed |
| CN-114917409-A | Composition based on hyaluronic acid | 瑞玞生物医学(深圳)有限公司 | 2022-08-19 | — | — | CN | claimed |
| CN-101420961-A | Reduction of the titratable acidity and the prevention of tooth and other bone degeneration | IP 6 RES INC (US) | 2009-04-29 | — | — | CN | claimed |
| EP-1998786-A2 | REDUCTION OF THE TITRATABLE ACIDITY AND THE PREVENTION OF TOOTH AND OTHER BONE DEGENERATION | IP-6 Research, Inc. (US) | 2008-12-10 | — | — | EP | claimed |
| WO-2007103110-A2 | REDUCTION OF THE TITRATABLE ACIDITY AND THE PREVENTION OF TOOTH AND OTHER BONE DEGENERATION | IP-6 RESEARCH INC. (US) | 2007-09-13 | — | — | WO | claimed |
| US-20070212449-A1 | Reduction of the titratable acidity and the prevention of tooth and other bone degeneration | IP-6 RESEARCH INC. | 2007-09-13 | — | — | US | claimed |
| US-4698387-A | Allosteric conjugates of hemoglobin and use as blood substitutes | INTERMEDICAT GMBH (CH) | 1987-10-06 | — | — | US | claimed |
| US-20250339537-A1 | STIMULI RESPONSIVE BLOCK COPOLYMERS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4429722-B1 | STIMULI RESPONSIVE BLOCK COPOLYMERS | BOSTON SCIENT SCIMED INC (US) | 2025-08-27 | — | — | EP | disclosed |
| US-12390530-B2 | Stimuli responsive block copolymers | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| EP-3873235-B1 | PHYTO-THERAPYC COMPOSITIONS USEFUL TO IMPROVE THE QUALITY OF SLEEP AND IN THE TREATMENT OF INSONNIA, ANXIETY AND DEPRESSION | GIOVANNONE DANIELE (IT) | 2025-02-19 | — | — | EP | disclosed |
| US-12220498-B2 | In situ solidifying solutions and methods of making and using thereof | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2025-02-11 | — | — | US | disclosed |
| EP-0422109-A4 | REDUCTION OF CELL PROLIFERATION AND ENHANCEMENT OF NK-CELL ACTIVITY | — | 1991-06-12 | — | — | EP | disclosed |
| EP-0422109-A1 | REDUCTION OF CELL PROLIFERATION AND ENHANCEMENT OF NK-CELL ACTIVITY. | SHAMSUDDIN ABULKALAM M (US) | 1991-04-17 | — | — | EP | disclosed |
| EP-0185404-B1 | STROMA-FREE HEMOGLOBIN SOLUTION, PROCESS FOR THE PREPARATION THEREOF AND ITS APPLICATION | EURO-TROL B.V. (NL) | 1990-05-02 | — | — | EP | disclosed |
| WO-1990000057-A1 | REDUCTION OF CELL PROLIFERATION AND ENHANCEMENT OF NK-CELL ACTIVITY | SHAMSUDDIN ABULKALAM M (US) | 1990-01-11 | — | — | WO | disclosed |
| US-4698387-A | Allosteric conjugates of hemoglobin and use as blood substitutes | INTERMEDICAT GMBH (CH) | 1987-10-06 | — | — | US | disclosed |
| US-4528181-A | Dentifrice containing dual sources of fluoride | COLGATE-PALMOLIVE COMPANY (US) | 1985-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12220498-B2 | In situ solidifying solutions and methods of making and using thereof | VCL, ILK, SELE | ITPR3 1817/4885BTN3A1 2545/4885ITPR2 3106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.